![](/scidirimg/clear.gif)
![How to Cite or Link Using DOI (Opens New Window) How to Cite or Link Using DOI (Opens New Window)](/scidirimg/icon_doi.gif)
Copyright © 2007 Elsevier Ireland Ltd All rights reserved.
Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung
FDG uptake was significantly higher in squamous cell carcinomas (mean SUV 13.4 ± 4.9, n = 8) compared to adenocarcinomas (7.1 ± 3.3, n = 8, p = 0.007), or large cell carcinomas (5.9 ± 1.9, n = 3, p = 0.02). The degree of FDG accumulation seemed to depend especially on GLUT-1, GLUT-3 and tumor cell differentiation. The summed standardized values of these three parameters correlated significantly with the SUV (r = 0.47, p = 0.05).
The present study supports the hypothesis that tumor cell differentiation in combination with overexpression of GLUT-1 and GLUT-3 determine the extent of FDG accumulation and that squamous cell carcinomas accumulate more FDG than adenocarcinomas or large cell carcinomas.
![]() | how('infobubble_2','mlktLink_2')" onMouseOut="InfoBubble.timeout()">FDG uptake, glucose transporter type 1, and Ki European Journal of Radiology |
![]() European Journal of Radiology, Volume 62, Issue 2, May 2007, Pages 214-219 Xuan Canh Nguyen, Won Woo Lee, Jin-Haeng Chung, So Yeon Park, Sook Whan Sung, Yu Kyeong Kim, Young So, Dong Soo Lee, June-Key Chung, Myung Chul Lee, Sang Eun Kim Abstract PurposeFDG uptake mediated by glucose transporter type 1 (Glut-1) and tumor proliferative activity assessed by Ki-67 expression provide prognostic information in patients with non-small-cell lung cancer (NSCLC). Here, we compared the prognostic significances of FDG uptake, and of Glut-1 and Ki-67 expressions in patients with NSCLC.MethodsNSCLC patients (n = 53, F:M = 16:37, age 61.9 ± 12.1 years) who underwent curative resection after FDG-PET were enrolled. Thirty-one patients had stage I, 15 stage II, and 7 stage III disease. Patients were treated by surgery only (n = 12), surgery plus adjuvant oral chemotherapy (n = 32), or surgery plus adjuvant intravenous chemo- or radio-therapy (n = 9). Maximum standardized FDG uptake values (maxSUV), and the Glut-1 and Ki-67 expressions of resected tumors were analyzed for correlations and relations with tumor recurrence. The median follow-up duration was 15 months. ResultsThirteen (24.5%) of the 53 patients experienced recurrence during a median follow-up of 8 months and significant correlations were found between maxSUV, Glut-1, and Ki-67 expressions (r = 0.48–0.79, p < 0.001). Univariate analysis revealed that disease-free survival (DFS) was significantly correlated with maxSUV (<7 versus ≥7, p = 0.001),%Ki-67 expression (<25%versus ≥25%, p = 0.047), tumor size (<3 cm versus ≥3 cm, p = 0.027), and tumor cell differentiation (well/moderate versus poor, p = 0.011). However, multivariate Cox proportional analysis identified maxSUV as the only determinant of DFS (p = 0.005). Patients with a maxSUV of ≥7 (n = 14) had a significantly lower 1-year DFS rate (57.1%) than those with a maxSUV of <7 (n = 39, 89.7%). ConclusionFDG uptake is more valuable than Glut-1 or Ki-67 expression in terms of predicting prognosis in patients with resected NSCLC. ![]() |
![]() | how('infobubble_3','mlktLink_3')" onMouseOut="InfoBubble.timeout()">FDG uptake and glucose transporter type 1 expression in... European Journal of Surgical Oncology |
![]() European Journal of Surgical Oncology, Volume 32, Issue 9, November 2006, Pages 989-995 J.-H. Chung, W.W. Lee, S.Y. Park, G. Choe, S.W. Sung, J.-K. Chung, M.C. Lee, S.E. Kim Abstract AimsFDG uptake in NSCLC is related to glucose transporter type 1 (Glut-1) expression. Here, we investigated the direct causal relationship between FDG uptake and Glut-1 expression to determine the role of Glut-1 in FDG uptake by malignant and benign lymph nodes (LNs).MethodsFifty-five curative lung resections in 53 NSCLC patients (male:female = 36:17, age = 62.0 ± 11.8 years) were included. Maximum standardized uptake values (maxSUVs) of LNs in preoperative whole body FDG-PET and Glut-1 immunostaining results were compared. ResultsOf 316 pathologically confirmed LNs, 12.3%(39/316) were malignant, and in malignant LNs, FDG positive LNs were no different from FDG negative LNs in terms of size (15.0 ± 6.7 mm vs 10.0 ± 6.1 mm, p > 0.05), or in terms of the proportion of LNs occupied by tumor (60.0 ± 28.8%vs 39.2 ± 38.4%, p > 0.05), but had greater percentages of Glut-1 positive cells in tumors (74.1 ± 31.8%vs 22.7 ± 18.7%, p < 0.01), and Glut-1 staining intensities (3.4 ± 0.9 vs 1.8 ± 1.3, p < 0.01). FDG negative malignant LNs featured cytoplasmic Glut-1 expression and adenocarcinoma. Glut-1 staining intensities were found to be significantly correlated with the maxSUVs of malignant LNs (ρ = 0.516, p < 0.05), but the percentages of Glut-1 positive cells in tumors were not (r = 0.2072, p > 0.05). Analysis of FDG positive benign LNs showed that maxSUV was not correlated with degree of follicular hyperplasia, or Glut-1 expression (p > 0.05). ConclusionsIntense Glut-1 immunoreactivity was found to be proportionally related to the degree of FDG uptake by malignant LNs in NSCLC. However, the finding that Glut-1 expression in lymphoid hyperplasia showed no correlation with FDG uptake in benign LNs requires further investigation. ![]() |
![]() | View More Related Articles |
Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung